



Universiteit  
Leiden  
The Netherlands

**Imatinib in patients with severe COVID-19: a randomised, doubleblind, placebo-controlled, clinical trial (vol 9, pg 957, 2021)**

Aman, J.; Duijvelaar, E.; Botros, L.; Kianzad, A.; Schippers, J.R.; Smeele, P.J.; ... ; Bogaard, H.J.

**Citation**

Aman, J., Duijvelaar, E., Botros, L., Kianzad, A., Schippers, J. R., Smeele, P. J., ... Bogaard, H. J. (2021). Imatinib in patients with severe COVID-19: a randomised, doubleblind, placebo-controlled, clinical trial (vol 9, pg 957, 2021). *The Lancet Respiratory Medicine*, 9(8), E82-E82. doi:10.1016/S2213-2600(21)00283-6

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3566366>

**Note:** To cite this publication please use the final published version (if applicable).

**Correction to  
Lancet Respir Med 2021;  
published online  
June 17, [https://doi.org/10.1016/S2213-2600\(21\)00237-X](https://doi.org/10.1016/S2213-2600(21)00237-X)**

Aman J, Duijvelaar E, Botros L, et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. *Lancet Respir Med* 2021; published online June 17. [https://doi.org/10.1016/S2213-2600\(21\)00237-X](https://doi.org/10.1016/S2213-2600(21)00237-X)—In this Article, the authors Elisabeth C W Neefjes', Jeroen N Wessel's, Carolina C Pamplona's, and Elise M A Slob's names were incorrect. Rianne J A Hoek's affiliation should have been "Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, VUMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands". These corrections have been made to the online version as of June 25, 2021, and will be made to the printed version.



Published Online  
June 25, 2021  
[https://doi.org/10.1016/S2213-2600\(21\)00283-6](https://doi.org/10.1016/S2213-2600(21)00283-6)